Salud financiera de hoja de balance de Centogene

Salud financiera controles de criterios 0/6

Centogene tiene un patrimonio de los accionistas total de €-25.3M y una deuda total de €65.8M, lo que sitúa su ratio deuda-patrimonio en -260.1%. Sus activos y pasivos totales son €77.2M y €102.4M respectivamente.

Información clave

-260.1%

Ratio deuda-patrimonio

€65.76m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€19.10m
Patrimonio	-€25.28m
Total pasivo	€102.44m
Activos totales	€77.16m

Actualizaciones recientes sobre salud financiera

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Nov 25

Recent updates

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Aug 06

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Feb 16

Análisis de la situación financiera

Pasivos a corto plazo: CNTG.F tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: CNTG.F tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: CNTG.F tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: CNTG.F tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Datos insuficientes para determinar si CNTG.F tiene suficiente cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si CNTG.F tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Centogene

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Centogene N.V. announced delayed 20-F filing

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene Receives Nasdaq Non-Compliance Notice

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Recent updates

Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F).

Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F).

Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer

Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD)

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

New major risk - Revenue and earnings growth

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

New minor risk - Shareholder dilution

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene GAAP EPS of -€0.28, revenue of €10.32M

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Consensus forecasts updated

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020)

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Chief Scientific Officer Philip Lambert has left the company

Executive Officer Richard Stoffelen has left the company

Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene reports Q1 results

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene, Alector initiate EFRONT study in frontotemporal dementia

Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting